The Claim
Propylthiouracil inhibits both outer ring deiodination of reverse T3 and inner ring deiodination of T3 sulfate in human liver microsomes with similar potency, with a Ki of 0.10–0.16 μmol/L.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Propylthiouracil reduces the breakdown of reverse T3 and T3 sulfate in human liver tissue samples at similar concentrations, with an inhibition constant between 0.10 and 0.16 micromoles per liter.
See the scientific wording
Propylthiouracil inhibits both outer ring deiodination of reverse T3 and inner ring deiodination of T3 sulfate in human liver microsomes with similar potency, with a Ki of 0.10–0.16 μmol/L.
A single enzyme in the liver removes iodine atoms from two different thyroid hormone molecules — reverse T3 and T3 sulfate — using the same active site. Propylthiouracil blocks this enzyme by binding to it in a way that prevents the enzyme from using its essential helper molecule, causing both hormone breakdown processes to stop at the same rate.
What the research says
1 studyStudy: Deiodination of thyroid hormone by human liver.
The study found that the drug propylthiouracil stops two different thyroid hormone breakdown processes in the liver at the same strength, meaning it likely targets the same enzyme for both. This matches exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.